Stayble Therapeutics reports additional data strengthening the STA363 treatment for pain caused by disc herniation
Stayble Therapeutics AB ("Stayble" or the "Company") has previously announced positive results from the Company's clinical phase 1b study in lumbar disc herniation (LDH). The study met its primary safety and tolerability endpoint. Additional data exhibit several positive outcomes, including a promising statistically significant reduction in disc volume compared to placebo-treated patients, and further analysis has generated key learnings regarding MRI changes that give STA363 critical competitive advantages.CEO Andreas Gerward, commentsThe additional analysis strengthens our belief in